Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Universität Hamburg · University Medical Center Hamburg-Eppendorf · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
593
total citations
- FWCI
- 34.66
- Percentile
- 100%
- References
- 23
Citations per year
Authors
8- CBCarsten BokemeyerCorresponding
Universität Hamburg, University Medical Center Hamburg-Eppendorf
- EVEric Van Cutsem
Universitair Ziekenhuis Leuven
- PRPhilippe Rougier
Université de Versailles Saint-Quentin-en-Yvelines, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou
- FCFortunato Ciardiello
University of Campania "Luigi Vanvitelli", University of Naples Federico II
- SHS. Heeger
Merck (Germany)
Topics & keywords
Topics
Keywords
- KRAS
- Cetuximab
- Medicine
- Internal medicine
- Oncology
- Colorectal cancer
- Hazard ratio
- Chemotherapy
No related works found for this paper.